Starpharma's DEP™ (Dendrimer-Enhanced Pharmaceuticals) drug delivery program stands out from other drug delivery systems due to its versatility and ability to enhance existing and novel therapies while reducing toxicities. DEP™ utilizes dendrimers, a type of molecule, to improve drug delivery by targeting specific tissues or cells, enhancing bioavailability, and extending the shelf life of drugs.
Here's a more detailed look at how Starpharma's DEP™ program differs from other drug delivery approaches:
1. Versatility and Platform Technology:
DEP™ is a platform technology:
This means it can be applied to a wide range of therapeutic modalities, including small molecules, peptides, proteins, and even nucleic acids like mRNA, making it applicable to various drug types.
Other systems may be more specific:
For example, some systems are designed for targeted delivery of a particular drug type, like antibody-drug conjugates (ADCs).
2. Enhanced Performance and Reduced Toxicities:
Improved efficacy:
DEP™ can enhance the effectiveness of drugs by improving their delivery to target sites.
Reduced side effects:
By targeting specific tissues, DEP™ can minimize exposure of the drug to healthy cells, reducing potential side effects and toxicities.
Other systems may have trade-offs:
Some systems may improve efficacy but might also increase toxicity, or vice versa.
3. Intellectual Property and Commercial Opportunities:
DEP™ allows for the creation of new intellectual property:
By enhancing existing drugs, DEP™ can extend their patent life and create new commercial opportunities.
Other systems may have limitations in this area:
Some systems may be less adaptable to extending existing drug patents or creating new intellectual property.
4. Localized and Targeted Delivery:
DEP™ enables more controlled and precise drug delivery:
This means the drug can be delivered to specific areas of the body, such as tumor tissues, minimizing exposure to healthy cells.
Other systems may have less control:
Some systems, like oral administration, may result in a more systemic distribution of the drug, leading to potential side effects.
In essence, Starpharma's DEP™ program offers a unique combination of versatility, enhanced performance, reduced toxicity, and commercial potential that differentiates it from other drug delivery approaches.
SPL Price at posting:
8.9¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)